Diagnostic efficacy of gadolinium-based contrast media, Contrast Media, Medical Radiology. Diagnostic Imaging, vol.2014, pp.181-191 ,
Imaging of brain metastases, Surg Neurol Int, vol.4, pp.209-219, 2013. ,
Epidemiology of brain metastases, Curr Oncol Rep, vol.14, pp.48-54, 2012. ,
Advocating the development of next-generation high-relaxivity gadolinium chelates for clinical magnetic resonance, Invest Radiol, vol.53, pp.381-389, 2018. ,
Effect of contrast dose and field strength in the magnetic resonance detection of brain metastases, Invest Radiol, vol.38, pp.415-422, 2003. ,
Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications, Chem Rev, vol.99, pp.2293-2352, 1999. ,
Nephrogenic systemic fibrosis and gadolinium-based contrast agents, Adv Chronic Kidney Dis, vol.18, pp.188-198, 2011. ,
Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?, Nephrol Dial Transplant, vol.21, pp.1104-1108, 2006. ,
Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging, J Am Soc Nephrol, vol.17, pp.2359-2362, 2006. ,
Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting, Eur J Radiol, vol.66, pp.230-234, 2008. ,
Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report, Br J Radiol, vol.87, 2014. ,
thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review, Biometals, vol.21, pp.469-490, 2008. ,
Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions, Eur Radiol, vol.18, pp.2164-2173, 2008. ,
Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents, Invest Radiol, vol.44, pp.226-233, 2009. ,
Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenineinduced renal failure, Toxicol Sci, vol.131, pp.259-270, 2013. ,
Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study, Invest Radiol, vol.46, pp.292-300, 2011. ,
, Gadopiclenol Physicochemical Profile, vol.54, issue.8, 2019.
The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: a critical update, Crit Rev Toxicol, vol.44, pp.895-913, 2014. ,
High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material, Radiology, vol.270, pp.834-841, 2014. ,
Extent of signal hyperintensity on unenhanced T1-weighted brain MR images after more than 35 administrations of linear gadolinium-based contrast agents, Radiology, vol.282, pp.516-525, 2017. ,
Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents: comparative study in rats, Invest Radiol, vol.52, pp.396-404, 2017. ,
Gadolinium retention in the rat brain: assessment of the amounts of insoluble gadolinium-containing species and intact gadolinium complexes after repeated administration of gadolinium-based contrast agents, Radiology, vol.285, pp.839-849, 2017. ,
One-year retention of gadolinium in the brain: comparison of gadodiamide and gadoterate meglumine in a rodent model, Radiology, vol.288, pp.424-433, 2018. ,
, EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans, 2017.
, Gadolinium-based Contrast Agents (GBCAs): Drug Safety Communication -Retained in Body; New Class Warnings, US Food and Drugs Agency (FDA), 2019.
Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence, AJNR Am J Neuroradiol, vol.35, pp.2215-2226, 2014. ,
Usefulness of double dose contrastenhanced magnetic resonance imaging for clear delineation of gross tumor volume in stereotactic radiotherapy treatment planning of metastatic brain tumors: a dose comparison study, J Radiat Res, vol.54, pp.135-139, 2013. ,
Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths, Invest Radiol, vol.40, pp.715-724, 2005. ,
Effects of diffusion on free precession in nuclear magnetic resonance experiments, Phys Rev, vol.94, pp.630-638, 1954. ,
Modified spin-echo method for measuring nuclear relaxation times, Rev Sci Instrum, vol.29, pp.688-691, 1958. ,
Complexing mechanism of the lanthanide cations Eu 3+ , Gd 3+ , and Tb 3+ with 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane (DOTA)-characterization of three successive complexing phases: study of the thermodynamic and structural properties of the complexes by potentiometry, luminescence spectroscopy, and EXAFS, Chemistry, vol.10, pp.5218-5232, 2004. ,
Study of formation of complexes in aqueous solutions. III. A new method for refinement of stability constants of complexes and other parameters of protometric titrations, Talanta, vol.34, pp.385-395, 1987. ,
Alternatives to GBCA: are we there yet?, Top Magn Reson Imaging, vol.25, pp.171-175, 2016. ,
Science to practice: will gadolinium chelates be replaced by iron chelates in MR imaging?, Radiology, vol.286, pp.409-411, 2018. ,
Low-molecular-weight iron chelates may be an alternative to gadolinium-based contrast agents for T1-weighted contrast-enhanced MR imaging, Radiology, vol.286, pp.537-546, 2018. ,
Scientific and industrial challenges of developing nanoparticle-based theranostics and multiple-modality contrast agents for clinical application, Nanoscale, vol.7, pp.16146-16150, 2015. ,
NMR relaxometric studies of Gd(III) complexes with heptadentate macrocyclic ligands, Magn Reson Chem, vol.36, pp.200-208, 1998. ,
Dynamic effects of pair correlation functions on spin relaxation by translational diffusion in liquids. II. Finite jumps and independent T1 processes, J Chem Phys, vol.68, pp.4034-4037, 1978. ,
Second coordination sphere water molecules and relaxivity of gadolinium (III) complexes: implication for MRI contrast agents, Eur J Inorg Chem, pp.399-407, 2000. ,
Equilibrium and formation/dissociation kinetics of some Ln(III)PCTA complexes, Inorg Chem, vol.45, pp.9269-9280, 2006. ,
Gd-DOTA, a potential MRI contrast agent. Current status of physicochemical knowledge, Invest Radiol, vol.23, pp.232-235, 1988. ,
A kinetic investigation of the lanthanide DOTA chelates. Stability and rates of formation and of dissociation of a macrocyclic gadolinium (III) polyazapolycarboxylic MRI contrast agent, Inorg Chem, vol.31, pp.1095-1099, 1992. ,
Gadolinium retention, brain T1 hyperintensity, and endogenous metals: a comparative study of macrocyclic versus linear gadolinium chelates in renally sensitized rats, Invest Radiol, vol.53, pp.518-528, 2018. ,
Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide, Br J Pharmacol, vol.165, pp.1151-1162, 2012. ,
Speciation of Gd-based MRI contrast agents and potential products of transmetalation with iron ions or parenteral iron supplements, Anal Bioanal Chem, vol.404, pp.2133-2141, 2012. ,
The role of phosphate on Omniscan® dechelation: an in vitro relaxivity study at pH 7, Biometals, vol.24, pp.759-768, 2011. ,
Gadolinium-containing magnetic resonance contrast media: investigation on the possible transchelation of Gd 3+ to the glycosaminoglycan heparin, Contrast Media Mol Imaging, vol.8, pp.108-116, 2013. ,
Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation, Biometals, vol.11, pp.113-123, 1998. ,
Cellular labeling with Gd(III) chelates: only high thermodynamic stabilities prevent the cells acting as 'sponges' of Gd 3+ ions, Contrast Media Mol Imaging, vol.1, pp.23-29, 2006. ,
Stability of MRI paramagnetic contrast media: a proton relaxometric protocol for transmetallation assessment, Invest Radiol, vol.36, pp.115-122, 2001. ,
Gadolinium toxicity: iron and ferroportin as central targets, Magn Reson Imaging, vol.34, pp.1373-1376, 2016. ,
Gadolinium-based contrast agents and NSF: evidence from animal experience, J Magn Reson Imaging, vol.30, pp.1268-1276, 2009. ,
Biodistribution of gadolinium-based contrast agents, including gadolinium deposition, J Magn Reson Imaging, vol.30, pp.1259-1267, 2009. ,
Partition coefficients and their uses, Chem Rev, vol.71, pp.525-616, 1971. ,
Using radiotracers to characterize magnetic resonance imaging contrast agents, Invest Radiol, vol.37, pp.107-113, 2002. ,
Determination of extracellular fluid volume in the dog with ferrocyanide, Pflugers Arch, vol.357, pp.275-290, 1975. ,
Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging, Eur J Radiol, vol.21, pp.1-10, 1995. ,
P03277-A new approach to achieve highcontrast enhancement: initial results of an experimental extracellular gadoliniumbased magnetic resonance contrast agent, Invest Radiol, vol.50, pp.835-842, 2015. ,
Ultra-high-field MR neuroimaging, AJNR Am J Neuroradiol, vol.36, pp.1204-1215, 2015. ,
ACR Appropriateness Criteria® pre-irradiation evaluation and management of brain metastases, Expert Panel on Radiation Oncology-Brain Metastases, vol.17, pp.880-886, 2014. ,
Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases, AJNR Am J Neuroradiol, vol.13, pp.335-345, 1992. ,
High-dose gadoteridol in MR imaging of intracranial neoplasms, J Magn Reson Imaging, vol.2, pp.9-18, 1992. ,
MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol, J Magn Reson Imaging, vol.4, pp.669-673, 1994. ,
Assessment of pharmacokinetic, pharmacodynamic profile, and tolerance of gadopiclenol, a new high relaxivity GBCA, in healthy subjects and patients with brain lesions (Phase I/IIa Study), Invest Radiol, vol.54, pp.396-402, 2019. ,